首页 | 官方网站   微博 | 高级检索  
     

99Tcm-His10-Annexin Ⅴ探测非小细胞肺癌细胞凋亡的实验研究
引用本文:郑玉民,王自正,颜珏,杨翔,华子春,方纬,孟庆乐,王峰.99Tcm-His10-Annexin Ⅴ探测非小细胞肺癌细胞凋亡的实验研究[J].中华核医学杂志,2008,28(6).
作者姓名:郑玉民  王自正  颜珏  杨翔  华子春  方纬  孟庆乐  王峰
作者单位:1. 中日友好医院核医学科,北京,100029
2. 南京医科大学附属南京第一医院核医学科
3. 南京大学医药生物技术国家重点实验室
4. 中国医学科学院、中国协和医科大学阜外心血管病医院核医学科
基金项目:国家自然科学基金,江苏省自然科学基金 
摘    要:目的 探讨99Tcm标记带有10个连续组氨酸的膜联蛋白Ⅴ(His10-Annexin Ⅴ)探测荷非小细胞肺癌(NSCLC)裸小鼠模型化疗后肿瘤细胞凋亡的可行性.方法 用99Tcm直接标记His10-Annexin Ⅴ.荷H460 NSCLC肿瘤裸小鼠模型20只,按体表面积以100 mg/m2剂量紫杉醇化疗诱导,分成未治疗(对照)、化疗诱导后24,48,72 h共4组.99Tcm-His10-Annexin Ⅴ显像探测化疗前后肿瘤组织细胞凋亡,计算肿瘤/对侧正常肌肉组织放射性比值(T/NT),测定每克组织百分注射剂量率(%ID/g).以99Tcm-IgG显像为对照,确定肿瘤的非特异性摄取.用流式细胞术(FCM)测定肿瘤组织活化半胱氨酸天冬氨酸蛋白水解酶(Caspase-3),光学显微镜HE及原位末端标记法(TUNEL)染色测定凋亡指数.采用SPSS 12.0软件进行统计学处理,运用单因素方差分析和直线相关分析(Pearson).结果 99Tcm-His10-Annexin V放化纯为(98.01±1.67)%.注射99Tcm-His10-Annexin V后2 h即可得到清晰图像,化疗诱导组肿瘤部位可见明显的放射性浓聚,化疗后24,48,72 h组的T/NT值分别为2.63±0.76,3.41±0.90,3.85±0.62;对照组T/NT值为1.42±0.19,F值分别为12.064,23.322,70.177,P均<0.01.未治疗组肿瘤仅有少量放射性摄取,为(1.09±0.18)%ID/g,化疗后肿瘤摄取明显增加,24,48,72 h肿瘤摄取分别为(2.55±0.73)、(3.60±1.09)、(3.73±0.97)%ID/g,明显高于未治疗组(F值分别为18.733,20.624,35.626,P均<0.01).99Tcm-IgG显像化疗组及对照组肿瘤均未见明显放射性浓聚.未治疗组活化Caspase-3为(3.70±0.74)%,化疗后24,48,72 h分别为(23.46±2.23)%、(62.85±6.13)%、(70.44±6.09)%,3个化疗诱导组和未治疗组相比差异均有统计学意义(F值分别为354.610,459.438,591.052,P均<0.01).光学显微镜HE及TUNEL染色法发现,未治疗组细胞凋亡指数为(3.31±0.61)%,化疗后24,48,72 h细胞凋亡指数分别为(32.90±6.64)%、<70.42±7.54)%、(83.23±9.71)%,化疗诱导组与对照组细胞凋亡指数差异均有统计学意义(F值分别为98.627,393.215,337.386,P均<0.01).T/NT值、肿瘤组织放射性摄取与活化Caspase-3及细胞凋亡指数均有很好的相关性(r=0.847,0.833,0.774,0.850,P均<0.01).结论 99Tcm-His10-Annexin V显像可早期探测NSCLC化疗后细胞凋亡,进而早期预测和评价肿瘤治疗疗效.

关 键 词:  非小细胞肺  细胞凋亡  膜联蛋白Ⅴ

In vivo detection of non-small cell lung cancer apoptosis with 99Tcm-His10-Annexin Ⅴ
Abstract:Objective Annex.in V, a human protein with a high affinity for phosphatidylserine, la-beled with 99Tcm, can detect apoptosis in vivo. To simplify the preparation and labeling of Annexin V for nu-clear medicine studies, we investigated the addition of peptide sequences that would directly form endogenous chelation sites for 99Tcm and the feasibility of 99Tcm-labeled Annexin Ⅴ recombinant with ten consecutive histi-dines (His10-Annexin Ⅴ) in detection of apoptosis in non-small cell lung cancer (NSCLC) after chemo-therapy. Methods 99Tcm-His10-Aunexin Ⅴ was prepared with direct-labelling method. Fifteen nude mice bearing H460 non-small cell lung cancer underwent chemotherapy by paclitaxel injection at 24 (n=5), 48(n=5) and 72 h (n=5), respectively. Another 5 untreated mice were used as control. 99Tcm-Annexin Ⅴwere injected intravenously and planar static images were acquired using a pin-hole collimator. The radioac-tivity ratio of tumor to non-tumor (T/NT) and tumor uptake (percentage activity of injection dose per gram of tissue, %ID/g) of 99Tcm-His10-Annexin Ⅴ were calculated. 99Tcm-IgG was used as control to determine the non-specific accumulation in tumor. Activated Caspase-3 was analyzed with flow cytometry. HE staining and terminal deoxynucleofidyl transferase mediated dUTP-biofin nick end labeling (TUNEL) assay were also performed to confirm the presence of apoptosis. SPSS 12.0 was used for statistical analysis. Analysis of vari-ance and the Pearson correlation coefficient were used. Results The radiochemical purity of 99Tcm-His10-Annexin Ⅴ was (98.01±1.67)%. Tumor uptake of 99Tcm-His10-Annexin Ⅴ was significant 2 h after injec-tion. In the treatment groups, the values Of T/NT were 2.63+0.76, 3.41 +0.90 and 3.85 +0.62, respec-tively at 24, 48, 72 h after chemotherapy, much higher than that of control (1.42±0.19). The difference between treatment and control groups was significant (F=12.064, 23.322, 70.177, respectively, all P<0.01). Tumor uptake in treatment groups was (2.55±0.73), (3.60±1.09) and (3.73±0.97) %ID/g at 24, 48 and72 h after chemotherapy, respectively. In the control group, it was (1.09±0.18) % ID/g.The tumor uptake in paclitaxel induced groups were significant higher than that of untreated group (F=18.733, 20.624, 35.626, respectivdy, all P<0.01). There was no conspicuous radioactivity in tumors with 99Tcm-IgG imaging. The percentage of activated Caspase-3 in tumor was (3.70±0.74)%, (23.46±2.23)%, (62.85±6.13)% and (70.44±6.09)% in control and treatment groups respectivdy. Histo-logical analysis of tumor with HE stained and TUNEL assay revealed that paclitaxel treatment significantly increased the percentage of apoptotic cells. The appearance of apoptotic bodies were seldom in the untreated group with an apoptotic index of (3.31±0.61)%, but elevated to (32.90±6.64)%, (70.42±7.54)%, (83.23±9.71)% at 24, 48, and 72 h after paclitaxel inducement, respectively, significantly higher than that in untreated group (F=98.627,393.215,337.386, all P<0.01). Furthermore, the ra-tin of T/NT and tumor uptake of 99Tcm-His10-Annexin Ⅴ correlated well with the activated Caspase-3 and apoptotic index (r=0.847, 0.833, 0.774, 0.850; all P<0.01). Conclusions The results demonstra-ted that 99Tcm-His10-Annexin Ⅴ imaging in vivo for detection of apoptosis in NSCLC after chemotherapy is feasible. His10-Annexin Ⅴ has the characteristics of a molecular probe in early prediction of cancer treat-ment efficacy.
Keywords:Carcinoma  non-small cell lung  Apoptosis  Aunexin Ⅴ
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号